Latest News

Filters close
Newswise: Diabetes researchers spot dangerous T cells in the pancreas—even in healthy people
12-Oct-2020 4:25 PM EDT
Diabetes researchers spot dangerous T cells in the pancreas—even in healthy people
La Jolla Institute for Immunology

It's long been thought that having "autoreactive" T cells in the pancreas was a sure sign of type 1 diabetes. Yet a new study led by scientists at La Jolla Institute for Immunology (LJI) shows that even healthy people have these cells lurking in the pancreas—in surprisingly high numbers.

Newswise: Every COVID-19 case seems different. These scientists want to know why.
Released: 6-Oct-2020 2:40 PM EDT
Every COVID-19 case seems different. These scientists want to know why.
La Jolla Institute for Immunology

A new international study led by scientists at La Jolla Institute for Immunology (LJI), The University of Liverpool and the University of Southampton is the first to give a detailed snapshot of how the body's CD4+ T cells respond to the SARS-CoV-2 virus. Among the findings, their work suggests that early in the illness, patients hospitalized with severe cases of COVID-19 develop a novel T cell subset that can potentially kill B cells and reduce antibody production.

Newswise: A step toward helping patients breathe deeply
Released: 24-Sep-2020 3:35 PM EDT
A step toward helping patients breathe deeply
La Jolla Institute for Immunology

In a new study, researchers at La Jolla Institute for Immunology (LJI) report that a protein called TL1A drives fibrosis in several mouse models, triggering tissue remodeling, and making it harder for lungs and airways to function normally.

Newswise: T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
Released: 16-Sep-2020 2:55 PM EDT
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
La Jolla Institute for Immunology

A multi-layered, virus-specific immune response is important for controlling SARS-CoV-2 during the acute phase of the infection and reducing COVID-19 disease severity, with the bulk of the evidence pointing to a much bigger role for T cells than antibodies.

Newswise: LJI scientists receive $3.5 million to investigate role of immune cells in Parkinson's disease
Released: 15-Sep-2020 1:45 PM EDT
LJI scientists receive $3.5 million to investigate role of immune cells in Parkinson's disease
La Jolla Institute for Immunology

Scientists at the La Jolla Institute for Immunology (LJI) have received $3.5 million as part of a team award from Aligning Science Across Parkinson’s (ASAP) to support a three-year study into how immune cells may contribute to Parkinson's disease.

Newswise:Video Embedded beating-hiv-and-covid-19-may-depend-on-tweaking-vaccine-molecules
VIDEO
Released: 27-Aug-2020 3:45 PM EDT
Beating HIV and COVID-19 may depend on tweaking vaccine molecules
La Jolla Institute for Immunology

In a new Immunity study, researchers at La Jolla Institute for Immunology (LJI) show that one way to improve the body's immune response to vaccines is to factor in antigen valency. Valency refers to the number of antibody binding sites on an antigen.

Newswise:Video Embedded blocking-nerve-signals-to-the-pancreas-halts-type-1-diabetes-onset-in-mice
VIDEO
23-Aug-2020 9:00 PM EDT
Blocking nerve signals to the pancreas halts type 1 diabetes onset in mice
La Jolla Institute for Immunology

Blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes.

Newswise: LJI team gets first-ever look at a rare but vital stem cell in humans
14-Aug-2020 5:45 PM EDT
LJI team gets first-ever look at a rare but vital stem cell in humans
La Jolla Institute for Immunology

Scientists at La Jolla Institute for Immunology (LJI) have tracked down the rare stem cells that generate neutrophils in human bone marrow. This research, published August 18, 2020, in Immunity, gives researchers a potential path for intervening in diseases where neutrophil development goes awry.

Newswise: Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
Released: 4-Aug-2020 10:00 AM EDT
Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
La Jolla Institute for Immunology

A new study led by scientists at La Jolla Institute for Immunology (LJI) shows that memory helper T cells that recognize common cold coronaviruses also recognize matching sites on SARS-CoV-2, the virus that causes COVID-19.

Newswise: T cells can shift from helping to harming in atherosclerosis
22-Jul-2020 8:05 PM EDT
T cells can shift from helping to harming in atherosclerosis
La Jolla Institute for Immunology

At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place. In a new study, LJI scientists show that certain T lymphocytes, a type of white blood cell, that start out trying to fight the disease can end up increasing inflammation and making atherosclerosis cases even worse.

Newswise: Researchers track down metabolic enzyme that protects against inflammation
17-Jul-2020 2:20 PM EDT
Researchers track down metabolic enzyme that protects against inflammation
La Jolla Institute for Immunology

A new study from scientists at the La Jolla Institute for Immunology (LJI) shows that a previously poorly understood enzyme actually inhibits inflammation in blood vessels. The research offers a potential path to treating DADA2, an inflammatory blood vessel disease in children that is similar to Kawasaki disease.

Newswise: From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
Released: 2-Jul-2020 12:05 PM EDT
From Wuhan to San Diego—How a mutation on the novel coronavirus has come to dominate the globe
La Jolla Institute for Immunology

Two variants of the novel coronavirus (SARS-CoV-2), called G614 and D614, were circulating in mid-March. A new study shows that the G version of the virus has come to dominate cases around the world. They report that this mutation does not make the virus more deadly, but it does help the virus copy itself, resulting in a higher viral load, or "titer," in patients.

Released: 29-Jun-2020 12:25 PM EDT
Even in the worst COVID-19 cases, the body launches immune cells to fight back
La Jolla Institute for Immunology

SHAREInternational collaboration provides important piece of COVID-19 puzzleLA JOLLA—A new study from researchers at La Jolla Institute for Immunology (LJI) and Erasmus University Medical Center (Erasmus MC) shows that even the sickest COVID-19 patients produce T cells that help fight the virus. The study offers further evidence that a COVID-19 vaccine will need to elicit T cells to work alongside antibodies.

Newswise: LJI Scientists Investigate a Powerful Protein Behind Antibody Development
17-Jun-2020 4:35 PM EDT
LJI Scientists Investigate a Powerful Protein Behind Antibody Development
La Jolla Institute for Immunology

Scientists at the La Jolla Institute for Immunology (LJI) have discovered a potential new way to better fight a range of infectious diseases, cancers and even autoimmune diseases. The new study, published recently in Nature Immunology, shows how a protein works as a “master regulator” in the immune system.

Newswise: LJI scientists uncover immune cells that may lower airway allergy and asthma risk
10-Jun-2020 5:05 PM EDT
LJI scientists uncover immune cells that may lower airway allergy and asthma risk
La Jolla Institute for Immunology

In a new Science Immunology study, published on June 12, 2020, scientists at La Jolla Institute for Immunology (LJI) offer a clue to why non-allergic people don’t have a strong reaction to house dust mites. They’ve uncovered a previously unknown subset of T cells that may control allergic immune reactions and asthma from ever developing in response to house dust mites—and other possible allergens.

Newswise: Fighting Mosquito-Borne Viruses Requires a Precise Balance of Immune Cells
4-Jun-2020 2:35 PM EDT
Fighting Mosquito-Borne Viruses Requires a Precise Balance of Immune Cells
La Jolla Institute for Immunology

In a new study, published June 5, 2020, in the Journal of Experimental Medicine, scientists at La Jolla Institute for Immunology (LJI) shows that antibodies against JEV are “cross-reactive” and can also recognize Zika virus. Unfortunately, these antibodies can actually make Zika cases more severe.

Newswise: What we can learn from SARS
Released: 22-May-2020 12:55 PM EDT
What we can learn from SARS
La Jolla Institute for Immunology

Seventeen years ago, another viral outbreak was in the news. People wore masks, many were nervous to fly. This outbreak, known as SARS, was caused by a type of coronavirus we now call SARS-CoV-1. The difference was that SARS-CoV-1 was controlled and the virus is all but extinct. The newspaper headlines became a distant memory.

Newswise: First detailed analysis of immune response to SARS-CoV-2 bodes well for COVID-19 vaccine development
Released: 14-May-2020 6:05 PM EDT
First detailed analysis of immune response to SARS-CoV-2 bodes well for COVID-19 vaccine development
La Jolla Institute for Immunology

A study by researchers at La Jolla Institute for Immunology documents a robust antiviral immune response to SARS-CoV-2 in a group of 20 adults who had recovered from COVID-19. The findings show that the body’s immune system is able to recognize SARS-CoV-2 in many ways, dispelling fears that the virus may elude ongoing efforts to create an effective vaccine.

Newswise: New research gives further evidence that autoimmunity plays a role in Parkinson’s disease
17-Apr-2020 4:55 PM EDT
New research gives further evidence that autoimmunity plays a role in Parkinson’s disease
La Jolla Institute for Immunology

A new study co-led by scientists at the La Jolla Institute for Immunology (LJI) adds increasing evidence that Parkinson’s disease is partly an autoimmune disease. In fact, the researchers report that signs of autoimmunity can appear in Parkinson’s disease patients years before their official diagnosis.

Newswise: Too Much Haste Leads to Little Speed
3-Apr-2020 10:45 AM EDT
Too Much Haste Leads to Little Speed
La Jolla Institute for Immunology

Researchers at the La Jolla Institute for Immunology (LJI) have written a new first draft chapter in the book of immunology. They have discovered a protective biological switch that, briefly, turns on the immune response at the first whiff of an invader—an important feature—but can also turn off potentially destructive immune rampage that may also occur. This “off” switch can protect against serious, life threatening inflammation.

Newswise: La Jolla Institute for Immunology to host coronavirus immunotherapy clearinghouse
26-Mar-2020 7:10 PM EDT
La Jolla Institute for Immunology to host coronavirus immunotherapy clearinghouse
La Jolla Institute for Immunology

La Jolla Institute for Immunology (LJI) has been awarded a $1.73 million grant by the Bill & Melinda Gates Foundation to establish a Coronavirus Immunotherapy Consortium (CoVIC) as part of the foundation’s global efforts to stem the tide of the current coronavirus outbreak.

Newswise: LJI scientists identify potential targets for immune responses to novel coronavirus
Released: 11-Mar-2020 6:15 PM EDT
LJI scientists identify potential targets for immune responses to novel coronavirus
La Jolla Institute for Immunology

Publishing in the March 16, 2020, online issue of Host, Cell and Microbe, a team of researchers at La Jolla Institute for Immunology, in collaboration with researchers at the J. Craig Venter Institute, provides the first analysis of potential targets for effective immune responses against the novel coronavirus. The researchers used existing data from known coronaviruses to predict which parts of SARS-CoV-2 are capable of activating the human immune system.

Newswise: Cellular culprit suspected of pushing dengue fever from bad to worse is cleared by advanced transcriptomics
19-Dec-2019 3:05 PM EST
Cellular culprit suspected of pushing dengue fever from bad to worse is cleared by advanced transcriptomics
La Jolla Institute for Immunology

No one knows what makes a mild dengue viral infection morph into a severe and sometimes deadly dengue hemorrhagic fever/dengue shock syndrome. Experts previously believed the likely cause was ramped up activity of T cells, which can massively boost an immune response to a virus. Now, however, researchers at the La Jolla Institute for Immunology (LJI), have found definitive evidence that CD4 T cells, one of two main subtypes of T cells, are not to blame.

Newswise: La Jolla Institute for Immunology acquires Berkeley Lights Beacon® platform
Released: 9-Dec-2019 1:00 AM EST
La Jolla Institute for Immunology acquires Berkeley Lights Beacon® platform
La Jolla Institute for Immunology

La Jolla Institute for Immunology (LJI) is placing their confidence in Berkeley Lights’ Beacon® Optofluidic Platform and B cell antibody discovery workflow to accelerate the discovery of rare and lifesaving antibodies for the treatment of re-emerging and emerging diseases.

Newswise: LJI researchers reveal unexpected versatility of an ancient DNA repair factor
26-Nov-2019 4:35 PM EST
LJI researchers reveal unexpected versatility of an ancient DNA repair factor
La Jolla Institute for Immunology

New work from the lab of La Jolla Institute for Immunology (LJI) investigator Anjana Rao, Ph.D., reveals a previously unrecognized activity for a highly conserved DNA repair factor. The study reports that mouse lymphocytes engineered to lack that protein (known as HMCES and pronounced Hem'-sez) cannot recombine their DNA in a manner necessary to make new classes of antibodies, called Immunoglobulins G or A (IgG or IgA).

Newswise: Seqster Signs 3-year License Agreement of SRP™ to 
La Jolla Institute of Immunology for Asthma Study
22-Oct-2019 11:30 AM EDT
Seqster Signs 3-year License Agreement of SRP™ to La Jolla Institute of Immunology for Asthma Study
La Jolla Institute for Immunology

Seqster, the award-winning SaaS-based technology platform enabling consumer-centered health data management, today announced a 3-year licensing deal and partnership with La Jolla Institute of Immunology (LJI) to support the execution of a $6.9 million Asthma study funded by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH NHLBI) that establishes one of only 10 PrecISE Network Clinical Centers nationwide.

Newswise: Lassa Virus’ Soft Spot Revealed
5-Aug-2019 8:05 AM EDT
Lassa Virus’ Soft Spot Revealed
La Jolla Institute for Immunology

A new study, led by researchers at La Jolla Institute for Immunology (LJI), identified and then reverse engineered the molecular properties shared by antibodies that are particularly efficient at inactivating or “neutralizing” Lassa virus providing a map for rational vaccine design.

Newswise: TET proteins: double agents in DNA methylation prevent catastrophic cancer
24-Jul-2019 2:45 PM EDT
TET proteins: double agents in DNA methylation prevent catastrophic cancer
La Jolla Institute for Immunology

In their latest study, published in this week’s online issue of Proceedings of the National Academy of Sciences, researchers at La Jolla Institute for Immunology (LJI), reveal how the finely tuned balance between DNA methylation and demethylation prevents genomic instability and cancer.

Newswise: No cell is an island
24-Jun-2019 5:05 PM EDT
No cell is an island
La Jolla Institute for Immunology

In a new study, published on June 25, 2019, in the journal eLife, the researchers report that higher levels of doublets can be found in people with severe cases of tuberculosis or dengue fever.

Newswise: To kill tumors, activate this elite group of T cells
Released: 21-Jun-2019 5:05 PM EDT
To kill tumors, activate this elite group of T cells
La Jolla Institute for Immunology

Tissue-resident memory T cells (TRMs) are known to help the body fight infection, but they are also key tumor fighters. A new study reveals that these cells are unique in their ability to seek out and kill tumor cells without suffering from the common phenomenon of T cell “exhaustion.”

Newswise: Eric Zwisler named Chair of La Jolla Institute for Immunology’s Board of Directors
Released: 3-Jun-2019 3:05 PM EDT
Eric Zwisler named Chair of La Jolla Institute for Immunology’s Board of Directors
La Jolla Institute for Immunology

Eric Zwisler, former President and Chairman of Cardinal Health China, has been elected Chairman of the Board of Directors of La Jolla Institute for Immunology. He will assume his role effective May 31, 2019.

Newswise: NIH awards $35 million grant to establish global Consortium to develop treatments for Ebola, Lassa and other viral threats
27-May-2019 12:05 PM EDT
NIH awards $35 million grant to establish global Consortium to develop treatments for Ebola, Lassa and other viral threats
La Jolla Institute for Immunology

La Jolla Institute Professor Erica Ollmann Saphire, Ph.D., will lead a five-year global effort totaling up to $35 million that brings together experts from around the world to streamline and accelerate the development of immunotherapeutics against emerging and re-emerging viral threats. The international consortium is funded through the Centers of Excellence for Translational Research (CETR) program at the National Institute of Allergy and Infectious Disease), part of the National Institutes of Health (NIH).

Newswise: De-TOXing exhausted T cells may bolster CAR T immunotherapy against solid tumors
23-May-2019 4:05 AM EDT
De-TOXing exhausted T cells may bolster CAR T immunotherapy against solid tumors
La Jolla Institute for Immunology

A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumor attack.

Newswise:Video Embedded in-nepal-with-dr-melanie-mccauley
VIDEO
Released: 16-May-2019 10:35 AM EDT
In Nepal with Dr. Melanie McCauley
La Jolla Institute for Immunology

”There's a lot of merit in bringing medicines to people who can't reach them themselves, but it's sort of putting a bandaid on the situation and I realized that only through scientific discovery will we really make huge changes that impact large populations of people. So that's why I started doing research and global health, specifically dengue virus and Zika virus.” —Dr. Melanie McCauley

Newswise:Video Embedded bill-the-carousel-guy
VIDEO
Released: 16-May-2019 10:35 AM EDT
Bill, the Carousel Guy
La Jolla Institute for Immunology

in 47 years operating the Balboa Park Carousel in San Diego, Bill Brown has only missed two weeks of work. For him, Life Without Disease means that he never has to miss another day.

Newswise:Video Embedded on-the-road-with-page-and-larry
VIDEO
Released: 15-May-2019 2:05 PM EDT
On the road with Page and Larry
La Jolla Institute for Immunology

Page and Larry have been exploring the world together since their days as high school sweethearts. For them, Life Without Disease means they can keep going wherever adventure leads them.

Newswise: New HIV  vaccine strategy “pumps” the immune system
6-May-2019 9:50 AM EDT
New HIV vaccine strategy “pumps” the immune system
La Jolla Institute for Immunology

A new HIV vaccine delivery strategy appears to enhance the protective immune response in a preclinical model. Scientists at the La Jolla Institute for Immunology (LJI) have discovered that delivering an HIV vaccine in small doses over a series of days leads to a stronger immune response than when the same vaccine is given all at once.

Newswise: TET gene mutations in T regulatory cells unleash fatal autoimmune disease in mice
30-Apr-2019 8:05 PM EDT
TET gene mutations in T regulatory cells unleash fatal autoimmune disease in mice
La Jolla Institute for Immunology

When TET2 and TET3 proteins are genetically deleted from T-regs in mice, their suppressive function is lost over time and animals develop inflammatory disease. More importantly, because these TET2 and TET3 mutant cells had once 'experienced' being a normal T-reg, they behaved very differently.

Newswise: TET proteins regulate factors essential for normal antibody production
24-Apr-2019 11:05 AM EDT
TET proteins regulate factors essential for normal antibody production
La Jolla Institute for Immunology

A new report by researchers at La Jolla Institute found that a genetic deletion, or mutation, of TET2 and TET3 in mouse B cells damps down the generation of functional IgG antibodies, decreasing the effectiveness of immune responses.

Newswise: To respond or tolerate? LJI researchers selectively block immune activation program orchestrated by the nuclear factor NFAT
Released: 22-Apr-2019 3:05 PM EDT
To respond or tolerate? LJI researchers selectively block immune activation program orchestrated by the nuclear factor NFAT
La Jolla Institute for Immunology

The immune system occasionally makes mistakes that require correction. For example, in autoimmunity, T-cells lose "immune tolerance" of self and can destroy one's very own tissues. Conversely, in cancer, the immune system can rapidly exhaust itself in the face of tumor antigens and become unresponsive, allowing tumors to thrive.

Newswise: Why your kid’s strep throat keeps coming back
4-Feb-2019 7:00 AM EST
Why your kid’s strep throat keeps coming back
La Jolla Institute for Immunology

Each year, some 600 million people around the world come down with strep throat. Yet, it was unclear why some kids are prone to repeated bouts of strep throat while others appear to be more or less immune. The latest study by researchers at La Jolla Institute for Immunology (LJI) provides the first clues why some children are more susceptible than others to contracting recurrent strep throat.

Newswise: La Jolla Institute Awarded Renewal of NIH Contract to Continue Its Role as Host of Immune Epitope Database
Released: 23-Jan-2019 4:05 PM EST
La Jolla Institute Awarded Renewal of NIH Contract to Continue Its Role as Host of Immune Epitope Database
La Jolla Institute for Immunology

La Jolla Institute for Immunology (LJI) has been awarded a $22 million contract renewal over seven years from the National Institutes of Health (NIH) to host and expand the Immune Epitope Database (IEDB). The database is the world’s most comprehensive collection of scientific data on how the immune system responds to a wide range of infectious agents, allergy-causing substances, and other stimuli that activate the immune system.

Newswise: La Jolla Institute for Immunology renews longtime collaboration with Kyowa Kirin Pharmaceutical Research, Inc.
Released: 18-Dec-2018 5:05 PM EST
La Jolla Institute for Immunology renews longtime collaboration with Kyowa Kirin Pharmaceutical Research, Inc.
La Jolla Institute for Immunology

La Jolla Institute for Immunology (LJI) and Kyowa Kirin Pharmaceutical Research, Inc. (KKR), a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (KHK), a global specialty pharmaceutical company, today announced the signing of a new agreement. The agreement extends the longest industry-academic collaboration in the world for another three-year term, through until the end of 2021.

Newswise: Dr. Matthias von Herrath named world’s leading type 1 diabetes expert
Released: 12-Dec-2018 11:05 AM EST
Dr. Matthias von Herrath named world’s leading type 1 diabetes expert
La Jolla Institute for Immunology

Dr. Matthias von Herrath, M.D., who founded the Type 1 Diabetes Center at La Jolla Institute for Immunology (LJI) has been identified as the world’s top expert in Type 1 Diabetes by Expertscape, an organization that provides tools to quickly and easily find the best clinicians or pioneering scientists specializing in a wide range of medical conditions or biomedical topics.

12-Nov-2018 12:05 PM EST
DICE: Immune cell atlas goes live
La Jolla Institute for Immunology

For more than four years, a team of LJI scientists led by Associate Professor Pandurangan Vijayanand, M.D., Ph.D., has been undertaking a massive immunoprofiling effort, detailing how variations in DNA sequence impact gene activity in different types of immune cells.

Newswise: Maternally-Acquired Zika Immunity Can Increase Dengue Disease Severity in Mouse Pups
8-Nov-2018 5:05 PM EST
Maternally-Acquired Zika Immunity Can Increase Dengue Disease Severity in Mouse Pups
La Jolla Institute for Immunology

In this study, La Jolla Institute for Immunology (LJI) investigator Sujan Shresta, Ph.D., who studies both dengue and Zika viruses, explored awhether maternal immunity to Zika virus, which is structurally and genetically similar to dengue, might trigger a severe response to dengue infection in offspring.

Newswise: Global immunoprofiling effort reveals multifunctional T cell response during Zika infection
Released: 13-Nov-2018 11:05 AM EST
Global immunoprofiling effort reveals multifunctional T cell response during Zika infection
La Jolla Institute for Immunology

The latest study by researchers at the La Jolla Institute for Immunology (LJI) and their collaborators provide the first in-depth characterization of the body’s cytotoxic T cell response to Zika, which plays an important role in providing protective immunity against Zika.

Newswise: LJI investigators discover how protein pair controls cellular calcium signals
26-Oct-2018 1:35 PM EDT
LJI investigators discover how protein pair controls cellular calcium signals
La Jolla Institute for Immunology

Two studies recently published by La Jolla Institute for Immunology (LJI) investigators Patrick Hogan, PhD, and Aparna Gudlur, PhD, report how a calcium-sensing protein called STIM1 signals that it's time to initiate calcium retrieval and then relays that message to its partner, the calcium channel ORAI.

Newswise: La Jolla Institute Receives $ 4.5 Mill Cancer Moonshot Award
Released: 18-Oct-2018 1:05 PM EDT
La Jolla Institute Receives $ 4.5 Mill Cancer Moonshot Award
La Jolla Institute for Immunology

Researchers at La Jolla Institute for Immunology (LJI) and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute’s Cancer Moonshot initiative. The funding will support research to develop new and improved immunotherapeutic treatment options for patients with head and neck cancer.


Showing results

150 of 142

close
0.41053